11:44 AM EDT, 04/02/2025 (MT Newswires) -- Hims & Hers Health's ( HIMS ) expanion of weight loss products on its telehealth platform to include generic Liraglutide is "incrementally positive," while Tirzepatide is unlikely to drive meaningful revenue contribution, Truist Securities said in a Tuesday note.

Truist said it Liraglutide could drive upside to its Q2 estimates for Hims & Hers Health ( HIMS ) and up to a $30 million upside for 2025. The investment firm also said more generic Liraglutide players could enter the market in H2, potentially leading to lower prices and incremental patient adoption.

The launch of Tirzepatide, however, seems like a marketing move to lure more consumers to Hims & Hers Health's ( HIMS ) platform, Truist added.

Truist Securities maintained its hold rating and $39 price target on Hims & Hers Health ( HIMS ).

Price: 30.45, Change: -0.60, Percent Change: -1.93